Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trialJames O. Lindsay, John A. Snowden, Mike Bradburn et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 19
Autologous stem cell transplantation with low-dose cyclophosphamide to improve mucosal healing in adults with refractory Crohn’s disease: the ASTIClite RCTJames O. Lindsay, John A. Snowden, Daniel Hind et al.|Efficacy and Mechanism Evaluation|2024Cited by 1